| Not Yet Recruiting | Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel NCT07200089 | Washington University School of Medicine | Phase 1 |
| Not Yet Recruiting | Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma NCT07456605 | University Health Network, Toronto | Phase 1 |
| Not Yet Recruiting | Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm NCT07421856 | Hebei Senlang Biotechnology Inc., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma NCT07096778 | CellCentric Ltd. | Phase 2 |
| Not Yet Recruiting | Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma NCT07191379 | Odense University Hospital | Phase 4 |
| Recruiting | Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse NCT06827860 | Larysa Sanchez | Phase 2 |
| Not Yet Recruiting | Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma NCT06880601 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 |
| Not Yet Recruiting | UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma NCT06698744 | David Wald | Phase 1 |
| Recruiting | HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM NCT06822972 | Duke University | Phase 2 |
| Recruiting | A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma NCT07075185 | Kelonia Therapeutics, Inc. | Phase 1 |
| Recruiting | Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma NCT07032129 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | Universal CAR-T Cell Therapy for MM NCT07248176 | Bioray Laboratories | N/A |
| Recruiting | Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma. NCT06846905 | University Hospital, Toulouse | — |
| Withdrawn | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs NCT04985357 | Travera Inc | — |
| Withdrawn | A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multipl NCT06411301 | Jules Bordet Institute | Phase 1 |
| Recruiting | A Trial of Selinexor, Ruxolitinib and Methylprednisolone NCT06225310 | Oncotherapeutics | Phase 1 |
| Recruiting | Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma NCT06485076 | University Health Network, Toronto | N/A |
| Recruiting | A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myelom NCT06115135 | Oncotherapeutics | Phase 2 |
| Recruiting | LMY-920 for Treatment of Relapsed or Refractory Myeloma NCT05546723 | Luminary Therapeutics | Phase 1 |
| Withdrawn | Marizomib Central Nervous System (CNS) NCT05050305 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting NCT05836896 | Technische Universität Dresden | Phase 1 |
| Recruiting | Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes NCT06282978 | PETHEMA Foundation | Phase 2 |
| Recruiting | All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple My NCT06158412 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Recruiting | BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma NCT06644443 | Shenzhen University General Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM NCT05909826 | Dong-A University Hospital | Phase 2 |
| Recruiting | Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory T(11;14) NCT05853965 | Universitätsklinikum Hamburg-Eppendorf | Phase 1 / Phase 2 |
| Unknown | Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM NCT05749133 | XuYan | Phase 1 / Phase 2 |
| Active Not Recruiting | Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma NCT05673083 | All4Cure | — |
| Unknown | Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM NCT05739188 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Phase 1 / Phase 2 |
| Completed | Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; th NCT05555329 | Amsterdam UMC, location VUmc | Phase 4 |
| Not Yet Recruiting | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumuma NCT05581875 | Hellenic Society of Hematology | Phase 1 / Phase 2 |
| Unknown | Long-term KRd in Relapsed and/or Refractory Multiple Myeloma NCT05495620 | Dong-A University Hospital | — |
| Unknown | Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment NCT06255847 | Shanxi Bethune Hospital | Phase 2 |
| Terminated | A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participa NCT05121103 | Epizyme, Inc. | Phase 1 |
| Recruiting | APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma NCT04657861 | Zhejiang University | EARLY_Phase 1 |
| Terminated | Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies NCT05191472 | Alfred Chung, MD | Phase 2 |
| Active Not Recruiting | Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma NCT04925193 | University of Colorado, Denver | Phase 2 |
| Recruiting | TriPRIL CAR T Cells in Multiple Myeloma NCT05020444 | Marcela V. Maus, M.D.,Ph.D. | Phase 1 |
| Unknown | Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma NCT04861480 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Unknown | A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients NCT04688853 | Gadeta B.V. | Phase 1 |
| Completed | Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carf NCT04813653 | Tel-Aviv Sourasky Medical Center | Phase 1 |
| Active Not Recruiting | Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed a NCT04790474 | Tel-Aviv Sourasky Medical Center | Phase 2 |
| Recruiting | a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plas NCT04776330 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignan NCT04603872 | Zhejiang University | EARLY_Phase 1 |
| Unknown | Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Rel NCT04287855 | Poitiers University Hospital | Phase 2 |
| Recruiting | Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM NCT04176718 | Andrew Yee, MD | Phase 2 |
| Active Not Recruiting | Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) NCT04184050 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Unknown | Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma NCT04272151 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | Ixazomib + Pomalidomide + Dexamethasone In MM NCT04094961 | Omar Nadeem, MD | Phase 1 / Phase 2 |
| Completed | Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma NCT03702725 | Alliance Foundation Trials, LLC. | Phase 1 |
| Active Not Recruiting | Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for NCT03836014 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Recruiting | BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma NCT04162353 | iCell Gene Therapeutics | Phase 1 |
| Completed | A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) NCT03650491 | Fortis Therapeutics, Inc. | Phase 1 |
| Recruiting | BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease NCT04271644 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Completed | TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refracto NCT03952091 | TJ Biopharma Co., Ltd. | Phase 3 |
| Terminated | Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma NCT03777410 | Travera Inc | — |
| Completed | TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma NCT03860038 | TJ Biopharma Co., Ltd. | Phase 2 |
| Unknown | Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma NCT03428373 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2 / Phase 3 |
| Unknown | Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma NCT04065308 | Seoul National University Hospital | Phase 2 |
| Completed | A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myelo NCT03697629 | Canadian Myeloma Research Group | Phase 2 |
| Unknown | Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM NCT03706547 | Peng Liu | Phase 1 |
| Terminated | Tinostamustine Conditioning and Autologous Stem Cell NCT03687125 | Mundipharma-EDO GmbH | Phase 1 / Phase 2 |
| Unknown | Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans NCT03601624 | Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado | Phase 2 |
| Unknown | CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma NCT03672253 | Second Affiliated Hospital of Xi'an Jiaotong University | Phase 1 |
| Unknown | Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma NCT03767725 | Shenzhen Second People's Hospital | Phase 1 |
| Terminated | Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma NCT03266692 | Cogent Biosciences, Inc. | Phase 1 |
| Active Not Recruiting | Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for R NCT03030261 | Washington University School of Medicine | Phase 2 |
| Completed | Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines NCT03155100 | Raija Silvennoinen | Phase 2 |
| Completed | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma NCT03136653 | Molecular Partners AG | Phase 1 / Phase 2 |
| Unknown | Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multip NCT04063189 | The First Hospital of Jilin University | Phase 2 |
| Completed | Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone o NCT02970747 | iOMEDICO AG | — |
| Unknown | Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients NCT02981199 | Chen Wenming | N/A |
| Terminated | Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myel NCT01889420 | New Mexico Cancer Research Alliance | Phase 1 |
| Completed | Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple M NCT02103335 | Celgene | Phase 1 |
| Completed | Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma NCT02176213 | Ajai Chari | Phase 2 |
| Unknown | Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma NCT02004275 | Alliance for Clinical Trials in Oncology | Phase 1 / Phase 2 |
| Completed | A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myel NCT01965353 | Dana-Farber Cancer Institute | Phase 1 |
| Terminated | Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse NCT01794572 | Institut Cancerologie de l'Ouest | N/A |
| Withdrawn | SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma NCT01329289 | University of Pittsburgh | Phase 2 |
| Unknown | Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Ce NCT01435720 | Senesco Technologies, Inc. | Phase 1 / Phase 2 |
| Completed | Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or NCT01394354 | University Hospital Freiburg | Phase 1 / Phase 2 |
| Completed | Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma NCT01083602 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple NCT00410605 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients NCT00401011 | AEterna Zentaris | Phase 1 / Phase 2 |
| Withdrawn | GO-203-2C + Bortezomib For Relapsed Or Refractory MM NCT02658396 | Dana-Farber Cancer Institute | Phase 1 |
| No Longer Available | Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Mye NCT02666209 | Dana-Farber Cancer Institute | — |